Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE-3: Empagliflozin as adjunct to insulin in type 1 diabetes
2014-005256-26Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Empagliflozin + insulin with Placebo + insulin (2 arms). Primary endpoint: Change from baseline in HbA1c. Started Aug 2015; status: completed.
02
Drugs
empagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2014-005256-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005256-26.